These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Plasma spermidine concentrations as early indication of response to therapy in human myeloma. Van Dobbenburgh OA; Houwen B; Jurjens H; Marrink J; Halie MR; Nieweg HO J Clin Pathol; 1983 Jul; 36(7):804-7. PubMed ID: 6863572 [TBL] [Abstract][Full Text] [Related]
6. Vindesine in refractory multiple myeloma. van der Lelie H; Monasch E; Pegels HG; von dem Borne AE Cancer; 1986 Jan; 57(2):226-9. PubMed ID: 3942957 [TBL] [Abstract][Full Text] [Related]
7. Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208). Kyle RA; Seligman BR; Wallace HJ; Silver RT; Glidewell O; Holland JF Cancer Chemother Rep; 1975; 59(3):557-62. PubMed ID: 1203882 [TBL] [Abstract][Full Text] [Related]
8. The current status and future prospects of treatment for multiple myeloma. Durie BG; Salmon SE Clin Haematol; 1982 Feb; 11(1):181-210. PubMed ID: 6176381 [No Abstract] [Full Text] [Related]
9. Combination of vindesine and prednisone in malignant lymphoma and acute leukemia. Raich PC; Walker BK; Rogers JS; Subramanian VP; Fontana JA; Knost JA; Denning B Cancer Treat Rep; 1983 May; 67(5):485-7. PubMed ID: 6573959 [TBL] [Abstract][Full Text] [Related]
10. Vindesine, prednisone, and daunomycin in acute lymphoblastic leukemia in relapse. Garay G; Milone J; Dibar E; Pavlovsky S; Kvicala R; Sackmann Muriel F; Montres Varela D; Eppinger-Helft M Cancer Chemother Pharmacol; 1983; 10(3):224-6. PubMed ID: 6345018 [TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU. Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704 [TBL] [Abstract][Full Text] [Related]
12. Vindesine and prednisone for remission induction in children with acute lymphocytic leukemia. Vats TS; Mehta P; Trueworthy RC; Smith SD; Klopovich P Cancer; 1981 Jun; 47(12):2789-92. PubMed ID: 6942907 [TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone. Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265 [No Abstract] [Full Text] [Related]
15. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251 [TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple myeloma. Alexanian R Acta Haematol; 1980; 63(5):237-40. PubMed ID: 6774549 [No Abstract] [Full Text] [Related]
17. Multiple myeloma with high tumour mass. Treatment with high-dose methylprednisolone, cyclophosphamide and vindesine. van Dobbenburgh OA; Halie MR; Piersma H; Marrink J; Ockhuizen T; Nieweg HO Eur J Cancer Clin Oncol; 1984 Mar; 20(3):437-9. PubMed ID: 6538503 [No Abstract] [Full Text] [Related]
18. Multiple myeloma: results with the M-2 protocol in a community hospital. Miller S; Perrotta AL J Am Osteopath Assoc; 1979 Aug; 78(12):857-64. PubMed ID: 489428 [No Abstract] [Full Text] [Related]
19. The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma. Cuttner J; Wasserman LR; Martz G; Sonntag RW; Kyle RA; Silver RT; Spurr C; Harley JB; Wiernik PM; Cornwell GG; Falkson G; Glidewell O; Holland JF Med Pediatr Oncol; 1975; 1(3):207-16. PubMed ID: 1232529 [TBL] [Abstract][Full Text] [Related]
20. OPP-EBV-CAD regimen as salvage treatment in advanced refractory or resistant multiple myeloma. Colombi M; Guffanti A; Alietti A; Latargia ML; Vener C; Maiolo AT; Baldini L Leuk Lymphoma; 2000 Dec; 40(1-2):87-94. PubMed ID: 11426632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]